FDA Accepts Drug Quality Of Life Claims From Secondary Endpoints - Bristol
Executive Summary
FDA sometimes allows quality of life claims for drugs based on secondary endpoints in clinical trials, Bristol-Myers Squibb Health Economics Policy & External Relations Group Director Joseph Jackson, PhD, told a Drug Information Association meeting March 12 in Washington, D.C.